17-17869344-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM2BP4
The NM_001082968.2(TOM1L2):āc.907G>Cā(p.Glu303Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000931 in 1,611,132 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000039 ( 0 hom., cov: 32)
Exomes š: 0.0000062 ( 0 hom. )
Consequence
TOM1L2
NM_001082968.2 missense
NM_001082968.2 missense
Scores
3
6
10
Clinical Significance
Conservation
PhyloP100: 7.83
Genes affected
TOM1L2 (HGNC:11984): (target of myb1 like 2 membrane trafficking protein) This gene belongs to a small gene family whose members have an N-terminal VHS domain followed by a GAT domain; domains which typically participate in vesicular trafficking. The canonical protein encoded by this gene also has a C-terminal clathrin binding motif. This protein has been shown to interact with Tollip, clathrin and ubiquitin and is thought to play a role in endosomal sorting. This gene resides in the 3.7 Mb deletion of chromosome region 17p11.2 that is associated with Smith-Magenis syndrome. Alternative splicing results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Apr 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.34581438).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TOM1L2 | NM_001082968.2 | c.907G>C | p.Glu303Gln | missense_variant | 8/15 | ENST00000379504.8 | NP_001076437.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TOM1L2 | ENST00000379504.8 | c.907G>C | p.Glu303Gln | missense_variant | 8/15 | 2 | NM_001082968.2 | ENSP00000368818.3 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 151798Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
151798
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000401 AC: 1AN: 249498Hom.: 0 AF XY: 0.00000741 AC XY: 1AN XY: 134968
GnomAD3 exomes
AF:
AC:
1
AN:
249498
Hom.:
AF XY:
AC XY:
1
AN XY:
134968
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000617 AC: 9AN: 1459222Hom.: 0 Cov.: 34 AF XY: 0.00000413 AC XY: 3AN XY: 726004
GnomAD4 exome
AF:
AC:
9
AN:
1459222
Hom.:
Cov.:
34
AF XY:
AC XY:
3
AN XY:
726004
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000395 AC: 6AN: 151910Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74258
GnomAD4 genome
AF:
AC:
6
AN:
151910
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74258
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 27, 2022 | The c.907G>C (p.E303Q) alteration is located in exon 8 (coding exon 8) of the TOM1L2 gene. This alteration results from a G to C substitution at nucleotide position 907, causing the glutamic acid (E) at amino acid position 303 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;.;T;.;.;.;T;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D;.;D;D;D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;.;M;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;.;N;.;N;N;N;D
REVEL
Benign
Sift
Benign
.;.;T;.;T;T;D;T
Sift4G
Benign
T;D;T;T;T;T;T;T
Polyphen
D;.;D;D;D;.;D;D
Vest4
MutPred
0.48
.;.;Gain of MoRF binding (P = 0.0201);.;.;.;.;.;
MVP
MPC
0.27
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at